Increased serum bilirubin level is related to good collateral development in patients with chronic total coronary occlusion

Internal Medicine

Volumn 51, Issue 3, 2012, Pages 249-255

  Erdoǧan, Turan ^a   Çiçek, Yüksel ^a   Kocaman, Sinan Altan ^b   Çanga, Aytun ^b   Çetin, Mustafa ^b   Durakoǧnlugil, Emre ^a   Şatiroǧlu, Ömer ^a   Temiz, Ahmet ^b   Ergül, Elif ^b   Şahin, Ismail ^b   Bostan, Mehmet ^a  

^a RECEP TAYYIP ERDOGAN UNIVERSITY   (Turkey)

^b Rize Education and Research Hospital ^*  (Turkey)

Author keywords

Anti oxidant; Bilirubin; Chronic total occlusion; Collateral development; Coronary artery disease; Glucose

Indexed keywords

BILIRUBIN; BILIRUBIN GLUCURONIDE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; COLLATERAL DEVELOPMENT; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOVASCULARIZATION (PATHOLOGY); OBSERVATIONAL STUDY;

EID: 84856578144     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.6417     Document Type: Article

References (43)

1. Gimbrone MA Jr, Topper JN, Nagel T, Anderson KR, Garcia Cardeña G. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann N Y Acad Sci 902: 230-239, 2000.
2. Habib GB, Heibig J, Forman SA, et al. Influence of coronary collateral vessels on myocardial infarct size in humans: results of phase I Thrombolysis in Myocardial Infarction (TIMI) trial. The TIMI Investigators. Circulation 83: 739-746, 1991.
3. Hansen JF. Coronary collateral circulation: clinical significance and influence on survival in patients with coronary artery occlusion. Am Heart J 117: 290-295, 1989.
4. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 235: 1043-1046, 1987.
5. Tanaka M, Fukui M, Tomiyasu K, et al. Low serum bilirubin concentration is associated with coronary artery calcification (CAC). Atherosclerosis 206: 287-291, 2009.
6. Schwertner HA, Jackson WG, Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 40: 18-23, 1994.
7. Breimer LH, Wannamethee G, Ebrahim S, Khoo JC, Witztum JL. Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin Chem 41: 1504-1508, 1995.
8. Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol 16: 250-255, 1996.
9. Troughton JA, Woodside JV, Young IS, et al; PRIME Study Group. Bilirubin and coronary heart disease risk in the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Eur J Cardiovasc Prev Rehabil 14: 79-84, 2007.
10. Rentrop KP, Cohen M, Blanke H, Phillips RA. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol 5: 587-592, 1985.
11. Kilian JG, Keech A, Adams MR, Celermajer DS. Coronary collateralisation: determinants of adequate distal vessel filling after arterial occlusion. Coron Artery Dis 13: 155-159, 2002.
12. Pohl T, Seiler C, Billinger M, et al. Frequency distribution of collateral flow and factors influencing collateral channel development. J Am Coll Cardiol 38: 1872-1878, 2001.
13. Sherman JA, Hall A, Malenka DJ, De Muinck ED, Simons M. Humoral and cellular factors responsible for coronary collateral formation. Am J Cardiol 98: 1194-1197, 2006.
14. Abaci A, O uzhan A, Kahraman S, et al. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation 99: 2239-2242, 1999.
15. Van Belle E, Rivard A, Chen D, et al. Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines. Circulation 96: 2667-2674, 1997.
16. Turhan H, Yasar AS, Erbay AR, Yetkin E, Sasmaz H, Sabah I. Impaired coronary collateral vessel development in patients with metabolic syndrome. Coron Artery Dis 16: 281-285, 2005.
17. Yilmaz MB, Biyikoglu SF, Akin Y, Guray U, Kisacik HL, Korkmaz S. Obesity is associated with impaired coronary collateral vessel development. Int J Obes 27: 1541-1545, 2003.
18. Torgerson JS, Lindroos AK, Sjostrom CD, Olsson R, Lissner L, Sjöström L. Are elevated aminotransferases and decresed bilirubin additional characteristic of the metabolic syndrome? Obes Res 5: 105-114, 1997.
19. Erdogan D, Gullu H, Yildirim E, et al. Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. Atherosclerosis 184: 431-437, 2006.
20. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 109(23 Suppl 1): III27-III32, 2004.
21. Vanhoutte PM. The endothelium-modulator of vascular smoothmuscle tone. N Engl J Med 319: 512-513, 1988.
22. Vítek L, Jirsa M, Brodanová M, et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 160: 449-456, 2002.
23. Perlstein TS, Pande RL, Beckman JA, Creager MA. Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004. Arterioscler Thromb Vasc Biol 28: 166-172, 2008.
24. Vítek L, Novotny' L, Sperl M, Holaj R, Spácil J. The inverse association of elevated serum bilirubin levels with subclinical carotid atherosclerosis. Cerebrovasc Dis 21: 408-414, 2006.
25. Wu TW, Fung KP, Yang CC. Unconjugated bilirubin inhibits the oxidation of human low density lipoprotein better than Trolox. Life Sci 54: 477-481, 1994. 340: 115-126, 1999.
26. Siow RC, Sato H, Mann GE. Heme oxgenase-carbon monoxide signaling pathway in atherosclerosis: anti-atherogenic actions of bilirubin and carbon monoxide? Cardiovasc Res 41: 385-394, 1999.
27. Stocker R, Glazer AN, Ames BN. Antioxidant activity of albumin bound bilirubin. Proc Natl Acad Sci USA 84: 5918-5922, 1987.
28. Neuzil J, Stocker R. Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J Biol Chem 269: 16712-16719, 1994.
29. Baranano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci USA 99: 16093-16098, 2002.
30. Wu TW, Carey D, Wu J, Sugiyama H. The cytoprotective effects of bilirubin and biliverdin on rat hepatocytes and human erythrocytes and the impact of albumin. Biochem Cell Biol 69: 828-834, 1991.
31. Wu TW, Wu J, Li RK, Mickle D, Carey D. Albumin-bound bilirubins protect human ventricular myocytes against oxyradical damage. Biochem Cell Biol 69: 683-688, 1991.
32. Wu TW, Fung KP, Wu J, Yang CC, Weisel RD. Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. Biochem Pharmacol 51: 859-862, 1996.
33. Mayer M. Association of serum bilirubin concentration with risk of coronary artery disease. Clin Chem 46: 1723-1727, 2000.
34. Ross R. Atherosclerosis-an inflamatory disease. N Engl J Med.
35. Mylonas C, Kouretas D. Lipid peroxidation and tissue damage. In Vivo 13: 295-309, 1999.
36. Hertog MGL, Feskens EJM, Hollman PCH, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 342: 1007-1011, 1993.
37. Frankel EN, Kanner J, German JB, Parks E, Kinsella JE. Inhibition of oxidation of human low-density lipoprotein by phenolic substances in red wine. Lancet 341: 454-457, 1993.
38. Kocaman SA, Sahinarslan A, Biberoglu G, et al. Asymmetric dimethyl arginine and coronary collateral vessel development. Coron Artery Dis 19: 469-474, 2008.
39. Kocaman SA. Asymmetric dimethyl arginine, NO and collateral growth. Anadolu KardiyolDerg 9: 417-420, 2009.
40. Gullu H, Erdogan D, Tok D, et al. High serum bilirubin concentrations preserve coronary flow reserve and coronary microvascular functions. Arterioscler Thromb Vasc Biol 25: 2289-2294, 2005.
41. Dekker D, Dorresteijn MJ, Pijnenburg M, et al. The bilirubinincreasing drug atazanavir improves endothelial function in patients with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 31: 458-463, 2011.
42. Durante W. Protective role of heme oxygenase-1 against inflammation in atherosclerosis. Front Biosci 17: 2372-2388, 2011.
43. George EM, Cockrell K, Aranay M, Csongradi E, Stec DE, Granger JP. Induction of heme oxygenase 1 attenuates placental ischemia-induced hypertension. Hypertension 57: 941-948, 2011.